0001437749-20-013681.txt : 20200623 0001437749-20-013681.hdr.sgml : 20200623 20200623164943 ACCESSION NUMBER: 0001437749-20-013681 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200619 FILED AS OF DATE: 20200623 DATE AS OF CHANGE: 20200623 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Das Asha CENTRAL INDEX KEY: 0001701647 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-23143 FILM NUMBER: 20982741 MAIL ADDRESS: STREET 1: C/O PROGENICS PHARMACEUTICALS, INC. STREET 2: 1 WORLD TRADE CENTER, 47TH FL, SUITE J CITY: NEW YORK STATE: NY ZIP: 10007 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: PROGENICS PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000835887 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 133379479 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: ONE WORLD TRADE CENTER STREET 2: 47TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10007 BUSINESS PHONE: 646-975-2500 MAIL ADDRESS: STREET 1: ONE WORLD TRADE CENTER STREET 2: 47TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10007 4 1 rdgdoc.xml FORM 4 X0306 4 2020-06-19 1 0000835887 PROGENICS PHARMACEUTICALS INC PGNX 0001701647 Das Asha ONE WORLD TRADE CENTER 47TH FLOOR, SUITE J NEW YORK NY 10007 1 Chief Medical Officer Stock Option (Right to Buy) 4.56 2020-06-19 4 D 0 125000 D 2029-02-01 Common Stock 125000 0 D Stock Option (Right to Buy) 4.77 2020-06-19 4 D 0 82214 D 2030-03-02 Common Stock 82214 0 D This option is scheduled to vest in annual installments over the five-year period commencing February 1, 2019. On June 19, 2020, pursuant to the Amended and Restated Agreement and Plan of Merger, dated February 20, 2020 (the "Merger Agreement") among Lantheus Holdings, Inc. ("Lantheus"), Plato Merger Sub, Inc., a wholly-owned subsidiary of Lantheus ("Merger Sub"), and Progenics Pharmaceuticals, Inc. ("Progenics"), Merger Sub merged with and into Progenics (the "Merger"), with Progenics surviving as a wholly-owned subsidiary of Lantheus. At the effective time of the Merger, this option was assumed by Lantheus and converted into an option to purchase Lantheus common stock based on an exchange ratio of 0.31 of a share of Lantheus common stock for each share of Progenics common stock subject to the option (with a corresponding adjustment being made to the exercise price of the option). Except for these adjustments, the current vesting and other terms of the option continue in effect. This option is scheduled to vest in annual installments over the three-year period commencing March 2, 2020. /s/ Asha Das 2020-06-23